Detail page

Knowledge Web

Person

Darja Karpova (1985-)

Name	Darja Karpova
Time	1985- (Date of birth and death)
Place	Brjansk (Geburtsort) Deutschland Russland
Further information	Diss. Fachbereich Biochemie, Chemie und Pharmazie der Univ. Frankfurt (Main)
Record type	Person
GND-Identifier	104670155X
Record ID	104670155X
Involved in show all Frequent whole blood donations select for DNMT3A variants mediating enhanced response to erythropoietin Hematopoietic-extrinsic cues dictate circadian redistribution of mature and immature hematopoietic cells in blood and spleen Variant rs1801157 in the 3'UTR of SDF-1ß Does Not Explain Variability of Healthy-Donor G-CSF Responsiveness Extracellular vesicle-mediated transfer of genetic information between the hematopoietic system and the brain in response to inflammation Rolle der CXCR4-CXCL12 Wechselwirkung in der unreifen Hämatopoiese : Untersuchungen mithilfe eines neuen CXCR4 Antagonisten The novel CXCR4 antagonist POL5551 mobilizes hematopoietic stem and progenitor cells with greater efficiency than Plerixafor

Please note

The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link:

Katalog der Deutschen Nationalbibliothek

Darja Karpova (1985-)

Frequent whole blood donations select for DNMT3A variants mediating enhanced response to erythropoietin

Hematopoietic-extrinsic cues dictate circadian redistribution of mature and immature hematopoietic cells in blood and spleen

Variant rs1801157 in the 3'UTR of SDF-1ß Does Not Explain Variability of Healthy-Donor G-CSF Responsiveness

Extracellular vesicle-mediated transfer of genetic information between the hematopoietic system and the brain in response to inflammation

Rolle der CXCR4-CXCL12 Wechselwirkung in der unreifen Hämatopoiese : Untersuchungen mithilfe eines neuen CXCR4 Antagonisten

The novel CXCR4 antagonist POL5551 mobilizes hematopoietic stem and progenitor cells with greater efficiency than Plerixafor